EU Approves Hospira's Inflectra In Biosimilars Milestone
Clearance was expected after European Medicines Agency officials earlier this year gave their blessing to Hospira's version of infliximab, a so-called monoclonal antibody drug that is more complex than any of the biosimilars previously approved in Europe.
Dr. Stan Bukofzer, chief medical officer at Hospira, called the authorization a "major milestone for Inflectra and...
Already a subscriber? Click here to login